Finance

Lists
Why is NGNE down 2.63%?
Dive Deeper
NGNE:NASDAQ
Neurogene Inc
$23.30
-2.63%
(-0.63) 1D
$23.30
0.00% (0.00)
After hours
Closed: Nov 16, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NGNE...
Open
$23.95
High
$24.65
Low
$23.18
Mkt. cap
482.33M
Avg. vol.
327.11K
Volume
244.34K
52-wk high
$43.66
52-wk low
$15.93
EPS
-$5.08
Beta
1.75
Shares outstanding
20.70M
No. of employees
131
Open
$23.95
High
$24.65
Low
$23.18
Mkt. cap
482.33M
Avg. vol.
327.11K
Volume
244.34K
52-wk high
$43.66
52-wk low
$15.93
EPS
-$5.08
Beta
1.75
Shares outstanding
20.70M
No. of employees
131
News stories
From web sources and news partners
About Neurogene Inc
CEOJonathan Drachman M.D.
Employees131
Founded2018
Headquarters-
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 4 analysts giving stock ratings to NGNE in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for NGNE in the last 3 months.
Highest
Current $23.30
$166.00 (+612.45%)
Average
$90.67 (+289.14%)
Lowest
$46.00 (+97.42%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$60.00
+157.5%
11/10/2026
Priyanka Grover
J.P. Morgan
Buy
Reiterated
-
-
11/09/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$166.00
+612.4%
11/10/2026
Paul Matteis
Stifel Nicolaus
Buy
Reiterated
$46.00
+97.4%
10/08/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
$81.00
+247.6%
08/11/2026
Ritu Baral
TD Cowen
Buy
Maintained
-
-
08/11/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/11/2026
Patrick Dolezal
LifeSci Capital
Buy
Maintained
$63.00
+170.4%
08/11/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
$70.00
+200.4%
06/03/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
$65.00
+179%
05/15/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
20.52M
25.15M
25.47M
23.52M
Cost of revenue
20.52M
25.15M
25.47M
23.52M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.89M
8.20M
11.20M
8.85M
Operating expense
6.89M
8.20M
11.20M
8.85M
Total operating expenses
27.41M
33.35M
36.67M
32.38M
Operating income
-27.41M
-33.35M
-36.67M
-32.38M
Other non operating income
122.00K
154.00K
136.00K
115.00K
EBT including unusual items
-24.74M
-30.93M
-34.49M
-29.02M
EBT excluding unusual items
-24.62M
-30.93M
-34.49M
-29.02M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-24.74M
-30.93M
-34.49M
-29.02M
Net profit margin
-
-
-
-
Earnings per share
-1.13
-1.39
-1.53
-1.05
Interest and investment income
2.67M
2.26M
2.05M
3.24M
Interest expense
-1.00K
-
-
-
Net interest expenses
2.67M
2.26M
2.05M
3.24M
Depreciation and amortization charges
-
-
-
-
EBITDA
-26.62M
-32.50M
-35.85M
-31.55M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps